toxogen GmbH is an enterprise
founded in 1997 on the basis of neurotoxin research done by its founders
at the Institute of Toxicology of Hannover Medical School.
The field of research
comprises the development of novel pharmacologically active proteins
derived from clostrial neurotoxins. These are bacterial pathogenicity
factors which act by a very specific modification of signal transduction
between peripheral nerves and their target organs.
Analytical methods were
developed which make possible the measurement of the activity of
clostridial neurotoxins at pg concentrations.
Furthermore, a reliable test
system was established for measuring neutralizing antibodies directed
against botulinum toxin types A and B. These may form in patients
treated with the respective neurotoxin over an extended period of time.
Until June 2008 toxogen was
based at the town of Langenhagen located near Hannover. Laboratory
activities proceeded in rented facilities at Hannover Medical School.
The activities widened to laboratories in Hannover Medical Park in July
2008. At the same time the company office was transferred to Hannover.
The business management passed
to Prof. Dr. Hans Bigalke on 1 July 2008.